Battle Against Johnson & Johnson "Texas Two-Step" Ploy Moves to New Jersey

In a new state court filing, women who hold Johnson & Johnson (NYSE:JNJ) and the company's iconic talc baby powder responsible for their ovarian cancer are seeking a temporary restraining order and preliminary injunction to prevent J&J, or any of its corporate affiliates, from fraudulently transferring assets to a subsidiary and plunging it into bankruptcy.

Faced with more than 34,000 ovarian cancer lawsuits, many consolidated in New Jersey federal court, J&J has told attorneys for the victims that the company is actively exploring options to transfer its potential talc-related liabilities – valued at approximately $24 billion – to a stand-alone subsidiary and seek bankruptcy protection for that business entity. Such a move would limit compensation for victims to pennies on the dollar and could bring an indefinite halt to all related trials scheduled in state courts across the nation, as well as the federal multidistrict litigation being heard in Trenton.

In a motion filed in Superior Court of New Jersey , attorneys for the plaintiffs argue that the bankruptcy strategy violates fraudulent conveyance laws in New Jersey and most other states. However, under a scheme known in legal circles as the "Texas Two-Step," economically viable companies can incorporate in Texas and then transfer liabilities to another entity with limited or no assets. As a result, a new company could be created by J&J to hold all legal liabilities but with limited or no funds to pay litigation claims.

In one recent case, In re DBMP LLC , U.S. Bankruptcy Judge J. Craig Whitley , in the Western District of North Carolina , was critical of the "Two Step" practice. In recent years, other companies such as Georgia-Pacific LLC have shifted asbestos liabilities to a separate company - with few if any assets - before placing it in bankruptcy.

"Plaintiffs deserve to have their day in court before a judge and jury, not arbitrarily placed in bankruptcy court with little hope of adequate compensation," says Andy Birchfield , Mass Tort Section Head of the Beasley Allen law firm , which represents thousands of ovarian cancer victims. "Bankruptcy should not be used as a ploy to delay or deny justice for the victims of a dangerous product produced by a company with hundreds of billions of dollars in assets."

The filing in New Jersey answers J&J complaints that a similar previous petition in Missouri unfairly burdened the company. "We'll take this cause to J&J's backyard where it cannot hide and avoid what is obviously a need for judicial oversight and intervention," says Michelle Parfitt , co-lead counsel in the Talcum Powder MDL and Senior Partner at Ashcraft and Gerel , who also represents the plaintiffs.

Dozens of peer-reviewed medical studies published in the last 35 years have found a statistically significant correlation between talcum powder use and ovarian cancer. Further research has confirmed that talc particles, when applied to the perineal area, can migrate to the ovaries, and result in inflammation and related malignancies. In December 2018 , Reuters reported that J&J knew for decades that its talc products were laced with asbestos but kept that information from regulators and the public.

"Companies that are bursting at the seams with available cash cannot be allowed to abuse the bankruptcy system this way," says Alexandra Walsh , founder of Walsh Law . "Make no mistake; this case is a wake-up call to anyone who is concerned about the rights of individuals, the right to trial by jury and the belief that huge corporations must play by the rules and accept responsibility when they commit wrong."

In May 2020 , Johnson & Johnson announced the company would no longer make nor market talc-based powders for the North American market.

In June, the U.S. Supreme Court declined to hear an appeal resulting from a $2.1 billion judgment against the company entered by the Missouri Court of Appeals and upheld by the Missouri Supreme Court. That appellate court found that J&J had engaged in "reprehensible conduct" for decades by repeatedly denying the presence of asbestos and the known association between talc use and ovarian cancer.

Media Contact:
Mike Androvett
214-507-5456
mike@androvett.com

Cision View original content: https://www.prnewswire.com/news-releases/battle-against-johnson--johnson-texas-two-step-ploy-moves-to-new-jersey-301368796.html

SOURCE Beasley Allen Law Firm

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Medical devices on a desk.

How to Invest in Medical Device Stocks and ETFs

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.

This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and prevention of diseases and physical conditions, and it continues to develop rapidly.

Examples of medical devices include neurostimulation devices, surgical implants, ultrasound imaging devices and robotic medical technology, along with insulin pumps and insulin pens for diabetes. Just as pharmaceutical companies seek to serve unmet needs, medical device companies do the same via innovative technologies.

Keep reading...Show less
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Latest Press Releases

Related News

×